Alnylam To Cut A Third Of Staff | Chemical & Engineering News
Volume 90 Issue 5 | p. 29 | Concentrates
Issue Date: January 30, 2012

Alnylam To Cut A Third Of Staff

Department: Business
Keywords: RNAi, biotech, hemophilia, jobs

Alnylam is making another round of job cuts as it sharpens its focus on the clinical development of its RNAi-based drug candidates. The Cambridge, Mass.-based company, which had 171 employees at the end of September 2011, will trim 33% of its workforce to save roughly $20 million this year. Alnylam will take a $4 million charge in the first quarter related to the restructuring. The move marks the second round of major layoffs at Alnylam, which in September 2010 shed a quarter of its staff after ending a five-year research collaboration with Novartis.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment